INVESTORS
Hatchtech investors include some of the largest and most influential life sciences investors in Australia:

• Biocomm

• GBS Venture Partners

• Queensland Biotechnology Fund

• Uniseed

• University of Melbourne Endowment Trust

• Westscheme

BOARD
Hatchtech has an experienced board of directors with skill sets and backgrounds spanning science, finance, business development, drug development and agricultural technology. The members
of the Hatchtech board are as follows:

• Dr Andrew Baker

• Dr John Kurek

• Dr Ross Macdonald

• Dr Stewart Washer (Chairman)

• [Dr Vernon Bowles, Company Secretary]

MANAGEMENT
Hatchtech's management team is a small but focused group that is leveraged by use of a global network of drug development, clinical (head lice),  veterinary, regulatory
and commercial contractors and advisors.

Hatchtech's team includes:

Dr Stewart Washer
CHAIRMAN
Stewart has over 17 years of senior executive and Board experience in commercial technology companies in the medical, food, agricultural and industrial sectors. He has raised over $50m in private shareholder and government funds to invest in his companies and was a founder of Biopacific Ventures, a $120m New Zealand based fund. He is currently a Venture Partner with the Swiss Inventages Fund, a €1.5 billion life science fund.

Dr Vern Bowles: 
CHIEF SCIENTIFIC OFFICER
Vern is the founder of Hatchtech and the research underpinning the core intellectual property is the culmination of 15 years of his work. He has devoted a significant proportion of his research career to studying the role of ectoparasite proteases in parasite infections, parasite nutrition and immune evasion. This work has been extended to the role of proteases in egg hatching in the sheep blowfly, head lice and other pests. Vern is an integral part of Hatchtech where he is responsible for the emerging crop and veterinary programmes and is also playing an important role in the back-up screening for new compounds for the head lice program. Vern is also the Deputy Director of the Centre for Animal Biotechnology in Melbourne.

Dr Lewis Schulz
CHIEF OPERATING OFFICER
Lewis has more than ten years first hand local and international experience with drug and device development. This has included the transfer of a new anti-inflammatory agent from the laboratory to the clinic and in this role he was responsible for the management of preclinical and clinical development activities. His previous experience also includes roles focussed on chemistry, manufacturing and regulatory affairs, and six years in European posts with international pharmaceutical companies. While working for Bristol Myers Squibb International, Lewis was instrumental in development and implementation of regulatory and marketing strategy for their oncology portfolio in the Central and Eastern European region.